Navigation Links
Sentrx Exits 2008 with Strong Growth

Sentrx, a New Jersey drug safety specialty firm, announced today that the company grew the number of pharmacovigilance outsourcing contracts by more than 50% in 2008. Revenues for the year increased 25% over 2007. The domestic service provider added long-term contracts in clinical trial and post-marketing safety, managed safety system hosting, and risk evaluation and mitigation strategies. The company maintained its strong record of regulatory compliance during this period of growth.

Little Falls, NJ (PRWEB) January 20, 2009 - Sentrx, the leading provider of drug safety services, announced today that the company grew the number of pharmacovigilance outsourcing contracts by more than 50% in 2008. Revenues for the year increased 25% over 2007.

Sentrx pioneered the concept of drug safety outsourcing and safety system hosting for clinical trials and post-marketed products in 1999. Since that time, Sentrx has provided operational and consulting services to nearly eighty unique clients. More than fifty of those companies have outsourced adverse event processing, safety system management, or risk evaluation and mitigation strategies (REMS) to Sentrx.

Sentrx provides services from its headquarters in Little Falls, NJ. In addition to a staff of office-based health care professionals, the company utilizes its network of highly experienced drug safety investigators across the United States. This flexible workforce allows Sentrx to handle volume fluctuations and extended coverage hours for its clients, which benefit from the quality, reliability and convenience of a domestic service provider.

Highlights of new business in 2008 include:

¨ Managed safety system hosting for seven biopharmaceutical companies and a large generic manufacturer
¨ Post-marketing safety surveillance for two specialty pharmaceutical companies
¨ Clinical trial safety monitoring for four biopharmaceutical companies
¨ REMS with Elements to Assure Safe Use for a biopharmaceutical company
¨ Safety system consulting engagements at three large companies
¨ Data migration projects at two specialty pharmaceutical companies
¨ Risk management plans authored and approved for two New Drug Applications
¨ Contract renewal and expansion with several existing clients

Other accomplishments in 2008 include:

¨ Installation of Phase Forward's Empirica™ Trace 4.2 in the Sentrx Hosting Center
¨ Implementation of the first hosted client on Empirica Trace
¨ Positive results from seventeen qualification inspections and client audits
¨ Participation in eleven regulatory health authority inspections conducted at client sites with no major findings

"Growing revenue 25 % is a great accomplishment for Sentrx," said Joseph Albano, Chief Executive Officer of Sentrx, "but I am most proud of our consistent record of compliance. As our client base grows, so does the level of scrutiny our people, processes and technology undergo. The regulatory audit results combined with our financial results demonstrate that Sentrx is the drug safety services provider that companies can rely on."

About Sentrx
Sentrx is a leading provider of technology-enabled solutions and services for global drug safety. Its mission is to help pharmaceutical, biotechnology, medical device, and consumer health companies document the safety profile of their products during clinical development and post-approval, enabling them to minimize risks and maximize benefits. Through its multilingual Safety Response Center in Little Falls, NJ, Sentrx delivers a unique combination of highly skilled people, exclusive technology, and best practices in drug safety monitoring. To learn more about Sentrx, please call 1-888-399-8032, extension 261; visit the Sentrx website at; or
view the Sentrx movie at


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Matching Genetics, Technology and Management Practices Critical to Meeting Strong Demand for Agricultural Crops
2. China Biologic Products Reports Strong Third Quarter 2008 Results
3. ACORN CRO Continues Growth in Strong Third Quarter
4. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
5. OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
6. Shires New Product Portfolio Delivers Strong Quarterly Performance
7. Cephalon Reports Another Strong Quarter
8. Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
9. Strong elasticity size effects in ZnO nanowires
10. Senetek Affirms Strong Financial Position
11. Dry adhesive based on carbon nanotubes gets stronger, with directional gripping ability
Post Your Comments:
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
Breaking Biology Technology:
(Date:11/20/2015)... November 20, 2015 NXTD ) ... on the growing mobile commerce market and creator of ... Pereira , was recently interviewed on The RedChip ... on this weekend on Bloomberg Europe , Bloomberg ... --> NXTD ) ("NXT-ID" or the "Company"), ...
(Date:11/19/2015)... , Nov. 19, 2015  Based on its in-depth ... Sullivan recognizes BIO-key with the 2015 Global Frost & ... Frost & Sullivan presents this award to the company ... to the needs of the market it serves. The ... meets and expands on customer base demands, the overall ...
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
Breaking Biology News(10 mins):